iBio, Inc. (NASDAQ: IBIO) announced financial results for the fiscal year ended June 30, 2025. CEO Martin Brenner highlighted the company’s progress in building a preclinical portfolio focused on cardiometabolic diseases and obesity, including the development of IBIO-610 and IBIO-600. The company also raised $6.2 million through a warrant inducement transaction and completed a $50 million public offering.
The company identified all four targets under its collaboration with AstralBio, focused on obesity and cardiometabolic disease, and added a fifth target. iBio in-licensed IBIO-600 and IBIO-610, progressing them through non-GLP non-human primate studies. They initiated an NHP study for IBIO-610 to evaluate efficacy in obese and elderly NHPs and developed a bispecific antibody targeting myostatin and activin A.
iBio began trading on the Nasdaq Stock Market under the ticker symbol “IBIO” and raised $6.2 million through a warrant inducement transaction with institutional investors. The company also completed a $50 million public offering and expanded its board with industry veterans David Arkowitz and António Parada. Felipe Duran, CFO of iBio, emphasized the company’s financial discipline and funding initiatives to advance its pipeline.
In the fiscal year ended June 30, 2025, iBio reported revenues of approximately $0.4 million, an increase from the previous year. Research and Development expenses increased to $8.3 million, while General and Administrative expenses decreased to $10.7 million. The company held cash, cash equivalents, and restricted cash of $8.8 million as of June 30, 2025.
iBio, Inc. leverages AI and advanced computational biology to develop biopharmaceuticals for various diseases. The company’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. Forward-looking statements in the press release highlight iBio’s focus on building a differentiated preclinical portfolio and developing breakthrough antibody treatments to address unmet medical needs.
Read more at GlobeNewswire: iBio Reports Fiscal Year 2025 Financial Results and